GlaxoSmithKline Stevenage, Stevenage, UK.
Institute for Lung Health, Department of Infection Immunity and Inflammation, University of Leicester, Respiratory Biomedical Research Unit University Hospitals of Leicester NHS Trust, Leicester, UK.
Clin Exp Allergy. 2017 Jul;47(7):890-899. doi: 10.1111/cea.12954. Epub 2017 Jun 16.
Patients with severe asthma appear relatively corticosteroid resistant. Corticosteroid responsiveness is closely related to the degree of eosinophilic airway inflammation. The extent to which eosinophilic airway inflammation in severe asthma responds to treatment with systemic corticosteroids is not clear.
To relate the physiological and inflammatory response to systemic corticosteroids in asthma to disease severity and the baseline extent of eosinophilic inflammation.
Patients with mild/moderate and severe asthma were investigated before and after 2 weeks of oral prednisolone (Clintrials.gov NCT00331058 and NCT00327197). We pooled the results from two studies with common protocols. The US study contained two independent centres and the UK one independent centre. The effect of oral corticosteroids on FEV , Pc20, airway inflammation and serum cytokines was investigated. Baseline measurements were compared with healthy subjects.
Thirty-two mild/moderate asthmatics, 50 severe asthmatics and 35 healthy subjects took part. At baseline, both groups of asthmatics had a lower FEV and Pc20 and increased eosinophilic inflammation compared to healthy subjects. The severe group had a lower FEV and more eosinophilic inflammation compared to mild/moderate asthmatics. Oral prednisolone caused a similar degree of suppression of eosinophilic inflammation in all compartments in both groups of asthmatics. There were small improvements in FEV and Pc20 for both mild/ moderate and severe asthmatics with a correlation between the baseline eosinophilic inflammation and the change in FEV . There was a ~50% reduction in the serum concentration of CXCL10 (IP-10), CCL22 (MDC), CCL17 (TARC), CCL-2 (MCP-1) and CCL-13 (MCP-4) in both asthma groups after oral corticosteroids.
Disease severity does not influence the response to systemic corticosteroids. The study does not therefore support the concept that severe asthma is associated with corticosteroid resistance. Only baseline eosinophilic inflammation was associated with the physiological response to corticosteroids, confirming the importance of measuring eosinophilic inflammation to guide corticosteroid use.
严重哮喘患者似乎对皮质类固醇相对耐药。皮质类固醇反应性与嗜酸性气道炎症的程度密切相关。严重哮喘中嗜酸性气道炎症对全身皮质类固醇治疗的反应程度尚不清楚。
将哮喘患者对全身皮质类固醇的生理和炎症反应与疾病严重程度和基线嗜酸性炎症程度相关联。
在口服泼尼松龙治疗前和治疗后 2 周,对轻度/中度和重度哮喘患者进行了研究(Clintrials.gov NCT00331058 和 NCT00327197)。我们合并了具有共同方案的两项研究的结果。美国的研究包含两个独立中心,英国的研究包含一个独立中心。研究了口服皮质类固醇对 FEV1、Pc20、气道炎症和血清细胞因子的影响。将基线测量值与健康受试者进行了比较。
32 名轻度/中度哮喘患者、50 名重度哮喘患者和 35 名健康受试者参与了研究。在基线时,两组哮喘患者的 FEV1 和 Pc20 均较低,且与健康受试者相比,嗜酸性粒细胞炎症增加。与轻度/中度哮喘患者相比,重度哮喘患者的 FEV1 更低,嗜酸性粒细胞炎症更多。口服泼尼松龙在两组哮喘患者的所有部位均引起相似程度的嗜酸性粒细胞炎症抑制。轻度/中度和重度哮喘患者的 FEV1 和 Pc20 均有较小程度的改善,且 FEV1 的变化与基线嗜酸性粒细胞炎症之间存在相关性。两组哮喘患者的血清 CXCL10(IP-10)、CCL22(MDC)、CCL17(TARC)、CCL-2(MCP-1)和 CCL-13(MCP-4)浓度均降低约 50%。
疾病严重程度并不影响全身皮质类固醇的反应。因此,该研究不支持严重哮喘与皮质类固醇耐药相关的概念。只有基线嗜酸性粒细胞炎症与皮质类固醇的生理反应相关,这证实了测量嗜酸性粒细胞炎症以指导皮质类固醇使用的重要性。